Poltreg SA is a Poland-based company engaged primarily in biotechnology and medical research. The Company conducts research in the field of autoimmunological diseases. The Company works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The Company works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The Company is developing its own research center, which is intended as a basic location for conducting future research activities.

Employees

Sector

Biotechnology & Medical Research

Calendar

09-09 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
06/08/26	PLN 26.00	+0.78%	3,637
05/08/26	PLN 25.80	+3.20%	16,629
04/08/26	PLN 25.00	+2.88%	9,450
03/08/26	PLN 24.30	+1.25%	5,087
31/07/26	PLN 24.00	0.00%	2,194

Delayed Quote Warsaw S.E.

More quotes

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Warsaw S.E. Other stock markets 19:55:43 06/08/2026 +04			5-day change	1st Jan Change
26.00 ^PLN	+0.78%		+8.33%	+6.12%

05-11	Poltreg S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-06	Poltreg S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	153M 40.91M 35.51M 33.25M 30.41M 57.41M 3.9B 58.16M 389M 1.95B 154M 150M 6.48B	P/E 2026 *	-4.91x	P/E 2027 *	6.74x
Enterprise Value	144M 38.58M 33.48M 31.35M 28.68M 54.14M 3.68B 54.85M 367M 1.84B 145M 142M 6.11B	EV / Sales 2026 *	120x	EV / Sales 2027 *	1.07x
Free-Float	72.15%	Yield 2026 *	-	Yield 2027 *	-

05-11	Poltreg S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-06	Poltreg S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-10	PolTREG SA Moves Forward With European Registration Process For TREG Therapy In Type 1 Diabetes	CI
11-19	Poltreg S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-07	Immuthera and Its Wholly Owned Subsidiary of Poltreg S.A Appoints Adrian Bot to Its Board of Directors	CI
10/09/25	Poltreg S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
04/08/25	PolTREG S.A. Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007	CI
01/08/25	Poltreg and Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial	CI
13/06/25	Poltreg Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy	CI
13/06/25	Poltreg Establishes U.S. Subsidiary Immuthera To Advance International Development Strategy	RE
15/05/25	PolTREG S.A. Announces Positive Ema Opinion on Pediatric Investigation Plan for PolTREG's Treg Therapy in Type 1 Diabetes	CI
14/05/25	Poltreg S.A. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
16/04/25	Poltreg S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

03-10	PolTREG moves forward with the European registration process for TREG therapy in type 1 diabetes	GL
11-07	Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies	GL
04/08/25	PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007	GL
31/07/25	PolTREG and U.S. Subsidiary Immuthera Secure Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial	GL
04/07/25	Immuthera’s Scientific Advisory Board: World-Leading Expertise Driving Next-Generation Diabetes and Immunotherapy Solutions	GL

Poltreg S.A. Stock

Stocks

PTG

PLPLTRG00038

Biotechnology & Medical Research

Valuation: Poltreg S.A.

Chart: Poltreg S.A.

Latest news : Poltreg S.A.

Press Releases: Poltreg S.A.

News in other languages: Poltreg S.A.

Quotes and Performance

Course Extremes

Managers and Directors: Poltreg S.A.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

03-11	PolTREG poursuit la procédure d’enregistrement au niveau européen de sa thérapie à base de TREG destinée au traitement du diabète de type 1
03-11	PolTREG treibt das europäische Zulassungsverfahren für die TREG-Therapie bei Typ-1-Diabetes voran

1 day	+0.78%
1 week	+8.33%
Current month	+8.33%
1 month	+41.69%
3 months	+51.16%
6 months	+0.39%
Current year	+6.12%

1 week	23	26.1
1 month	17.55	26.1
Current year	16	28.6
1 year	16	32.7
3 years	16	65
5 years	16	73.9
10 years	16	73.9

Manager	Title	Age	Since
Piotr Trzonkowski CEO	Chief Executive Officer	-	01/05/2019
Marta Druch CTO	Chief Tech/Sci/R&D Officer	-	01/11/2021
Daniel Shelly PRN	Corporate Officer/Principal	-	21/02/2024

Director	Title	Age	Since
Marcin Jerzy Mierzwiñski CHM	Chairman	-	24/05/2021
Oktawian Zbigniew Jaworek BRD	Director/Board Member	51	21/05/2021
Wojciech Golak BRD	Director/Board Member	43	01/06/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
POLTREG S.A.	+0.78%	+8.33%	-13.33%	-60.00%	40.99M
LONZA GROUP AG	+0.93%	-0.63%	+3.89%	+15.59%	48.57B
REVOLUTION MEDICINES, INC.	-0.71%	+2.09%	+435.03%	+561.93%	41.95B
IQVIA HOLDINGS INC.	-2.30%	-3.12%	+29.79%	+5.04%	38.85B
BEONE MEDICINES AG	-0.07%	+1.47%	+9.48%	+74.29%	37.24B
CELLTRION, INC.	+2.47%	+8.33%	+15.16%	+48.37%	30.67B
MEDPACE HOLDINGS, INC.	-1.15%	+0.61%	+35.19%	+123.43%	16.41B
ASCENDIS PHARMA A/S	+2.09%	-1.10%	-	-	16.1B
EUROFINS SCIENTIFIC SE	+0.29%	+1.87%	+8.17%	+19.01%	13.97B
ICON PUBLIC LIMITED COMPANY	-1.65%	-2.92%	+3.40%	-36.12%	12.62B
Average	+0.08%	+0.99%	+58.53%	+83.50%	25.64B
Weighted average by Cap.	+0.01%	+0.40%	+87.99%	+127.36%

	2026 *	2027 *
Net sales	1.2M 322K 279K 261K 239K 451K 30.64M 457K 3.06M 15.31M 1.21M 1.18M 50.95M	116M 31.2M 27.08M 25.35M 23.19M 43.78M 2.97B 44.35M 297M 1.48B 117M 115M 4.94B
Net income	-29.4M -7.88M -6.84M -6.4M -5.86M -11.06M -751M -11.2M -74.91M -375M -29.59M -28.94M -1.25B	24.2M 6.49M 5.63M 5.27M 4.82M 9.1M 618M 9.22M 61.66M 309M 24.35M 23.83M 1.03B
Net Debt	-8.7M -2.33M -2.02M -1.89M -1.73M -3.27M -222M -3.32M -22.17M -111M -8.76M -8.57M -369M	-28.4M -7.61M -6.61M -6.19M -5.66M -10.68M -725M -10.82M -72.37M -362M -28.58M -27.96M -1.21B